Peak Pharmaceutical has another postdoctoral entrance to open the topic.
Release time:
2023-06-25
On the afternoon of June 15, the post-doctoral research station of Jianfeng Pharmaceutical held a review meeting for Dr. Wu Zhuo from Donghua University.
Dr. Wu Zhuo's main research directions are research and development of new cardiovascular and cerebrovascular drugs, total synthesis of natural products, and organic synthesis technology. He has published more than ten papers in internationally renowned academic journals such as Eur. J. Med. Chem, and has won many excellent papers awards at the annual meeting of microbiology and biochemical drugs of Shanghai Pharmaceutical Association. Dr. Wu Zhuo's research project in the post-doctoral research station of Jianfeng Pharmaceutical is entitled "Design, synthesis and anti-tumor mechanism of oxindole compounds based on p53 target". At the opening review meeting, he elaborated on the background of the research project, the significance of the topic, the key problems to be solved, the solution plan, the main technical difficulties and innovation points, the work schedule and the budget, and accepted the questions and comments of the expert group.
The expert group of the opening review meeting is headed by Professor Chen Zhilong of Donghua University. Its members include Professor Wu Fanhong of Shanghai University of Applied Technology, Professor Fang Weijie of Zhejiang University's School of Pharmacy, Professor Jin Zhunian of Jinhua Vocational and Technical College of Pharmacy and Dr. Zhang Qiang, chief scientist of Jianfeng Pharmaceutical. Among them, Professor Chen Zhilong and Dr. Zhang Qiang will serve as Dr. Wu Zhuo's on-site co-site mentors respectively. Leaders of Jinhua Human Resources and Social Security Bureau, Science and Technology Bureau, Jinhua Development Zone Organization Human Resources and Social Security Bureau and other relevant departments, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, also attended the meeting. Jiang Xiaomeng, the host of the
opening review meeting, expressed his heartfelt thanks to all the leading experts for their arrival, and briefly introduced the development process of Jianfeng Pharmaceutical, and affirmed the work achievements of the postdoctoral workstation that has been rated as an excellent workstation for many years. He believes that Dr. Wu Zhuo's inbound research project has scientific significance and application value, and expects the research project to achieve the desired results. Huang Jinlong said that the P53 target is an important anti-cancer target that is currently being focused on at home and abroad. It is believed that with the continuous deepening of the research on this target, it will play a positive role in promoting the research and application of anti-cancer drugs. The company will fully support the research of this subject, provide all-round protection in terms of talents, equipment, funds, etc., and require Dr. Zhang Qiang to spend more energy to guide and participate in project research, I look forward to the early results and the early completion of the project.
After discussion, the expert group believed that Dr. Wu Zhuo's research project was selected appropriately, based on sufficient basis, with clear objectives and requirements, and the design scheme was feasible. He himself was capable of undertaking the research of the subject, and the relevant funds and schedule were reasonable. He agreed to open the topic. (Zhu Ningyan)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page